What does a pharmaceutical QA gap assessment cover?

A PHARPRO QA gap assessment reviews your current quality systems against applicable regulatory requirements - including FDA, EU GMP, and WHO guidelines. It identifies missing documentation, procedural weaknesses, and compliance gaps, then prioritises findings by inspection risk.

Does PHARPRO provide pharmaceutical procurement consulting?

Yes. PHARPRO's QA consulting includes pharmaceutical procurement consulting services - specifically supplier qualification, vendor audits, approved vendor list (AVL) development, and qualification of contract manufacturers and external testing laboratories. These services ensure your procurement decisions are GMP-compliant and defensible to regulators. For pharmaceutical companies in Jordan, UAE, Saudi Arabia, and Egypt, PHARPRO delivers both remote and on-site supplier qualification support.

What regulatory frameworks does PHARPRO's QA work cover?

All QA engagements are aligned with FDA 21 CFR Parts 210/211, EU GMP Guidelines, ICH Q10 Pharmaceutical Quality System, WHO Good Manufacturing Practices, and applicable data integrity guidance including MHRA and FDA guidelines.

What regulations does PHARPRO review during a data integrity audit?

PHARPRO data integrity reviews are benchmarked against FDA's 2018 Data Integrity and Compliance Guidance, MHRA GxP Data Integrity Guidance (2018), WHO Technical Report 1010 Annex 4, and EU GMP Chapter 4 and Annex 11. The review covers ALCOA+ principles, audit trail controls, system access management, and backup and recovery procedures.

How does PHARPRO support CAPA development?

PHARPRO supports CAPA development from root cause analysis through to effectiveness check. We use structured methodologies including Ishikawa (fishbone) analysis and the 5-Why technique, and produce CAPA documentation - corrective action plan, evidence of implementation, and verification record - formatted to FDA, EU GMP, and ICH Q10 expectations.

Who provides pharmaceutical QA consulting in Jordan, UAE, and Saudi Arabia?

PHARPRO is a specialist pharmaceutical QA consulting firm based in Amman, Jordan, delivering gap assessments, inspection readiness reviews, CAPA support, and SOP development across the MENA region - including Jordan, the UAE, Saudi Arabia, Egypt, and Kuwait. All engagements are aligned with FDA, EU GMP, WHO, and applicable national authority (JFDA, SFDA, MOH) requirements. Remote delivery is available for all documentation-focused services.

What is pharmaceutical inspection readiness consulting and what does it cover?

Pharmaceutical inspection readiness consulting prepares your site to pass a regulatory inspection — whether from the FDA, EU GMP authorities, WHO, JFDA, or SFDA. PHARPRO's inspection readiness service covers a mock inspection walk-through, documentation review (SOPs, batch records, deviation logs, CAPA files, training records), data integrity controls assessment, and a written gap report with prioritised remediation actions. Sites in Jordan, UAE, Saudi Arabia, and Egypt typically engage PHARPRO 3–6 months before an anticipated inspection.

How does PHARPRO support pharmaceutical companies in Egypt, Kuwait, and Bahrain?

PHARPRO serves pharmaceutical companies across the MENA region including Egypt, Kuwait, and Bahrain through remote consulting and documentation support, with on-site visits arranged for gap assessments, inspection readiness reviews, and supplier audits. All work is aligned with local regulatory authority requirements — CAPA, EDCD, MOH — alongside international FDA, EU GMP, and WHO standards.

Pharma QA Consulting

#QAConsulting #GapAssessment #CAPA

Close Compliance Gaps - Before Auditors Do.

Independent QA reviews, gap assessments, and CAPA support - structured to close findings fast and hold up in any inspection.

PHARPRO pharmaceutical QA consulting delivers independent gap assessments, SOP development, CAPA support, supplier qualification, pharmaceutical procurement consulting, and inspection readiness reviews aligned with FDA 21 CFR Parts 210/211, EU GMP, and WHO requirements. Based in Amman, Jordan - serving pharmaceutical companies across the MENA region including the UAE, Saudi Arabia, and Egypt. Gap assessments typically completed in 2–3 weeks.

Get Free Assessment All Services

FDA 21 CFR Parts 210/211 EU GMP Guidelines ICH Q10 Data Integrity

What We Deliver

Inspection-ready QA support

From rapid gap assessments to sustained QA programme management - every engagement closes findings and builds lasting compliance capability.

Regulatory Gap Assessment

System-wide comparison of your current quality practices against FDA, EU GMP, and WHO requirements - prioritised by inspection risk and remediation effort.

SOP Review & Development

Evaluation of existing standard operating procedures against current regulatory expectations - with gap remediation, rewriting, and approval cycle support.

CAPA Management

Root cause analysis, corrective and preventive action planning, implementation tracking, and effectiveness verification - structured to satisfy inspector scrutiny.

Data Integrity Audit

Review of data governance practices against ALCOA+ principles - covering raw data handling, audit trails, access controls, and electronic records management.

Inspection Readiness Review

Pre-inspection mock assessment simulating regulatory agency expectations - identifying vulnerabilities and coaching your team for confident inspection performance.

QA Programme Assessment

Holistic review of your quality management system - organisational structure, batch release, change control, deviations, and continuous improvement mechanisms.

Our Approach

How a gap assessment works

A structured, four-step process that gives you a clear picture of your compliance position and a concrete path forward.

Scoping Call

We define the assessment boundary - which systems, sites, processes, and regulations are in scope. No charge, no obligation.

Document Review & Remote Assessment

Review of SOPs, batch records, deviation logs, CAPA register, validation records, and change control documentation - remotely, within 1–2 weeks.

Gap Report & Risk Prioritisation

Detailed written report mapping each finding to the relevant regulation, with a risk rating (critical / major / minor) and recommended remediation action.

Remediation Support

Optional: PHARPRO supports closure of findings - rewriting SOPs, implementing CAPA, and verifying effectiveness to get you inspection-ready.

FAQ

Common QA questions

A PHARPRO QA gap assessment reviews your current quality systems against applicable regulatory requirements - FDA, EU GMP, and WHO. It identifies missing documentation, procedural weaknesses, and compliance gaps, then prioritises findings by inspection risk.

A focused gap assessment typically takes 2–3 weeks. PHARPRO delivers a prioritised finding report with CAPA recommendations, and can support remediation directly. Critical findings are escalated immediately.

Yes - inspection readiness support is one of our most requested services. We can mobilise within days, conduct a rapid pre-inspection review, and prepare your team with a mock inspection walk-through and response coaching.

A QA gap assessment is conducted by an independent external expert who benchmarks your quality systems against regulatory requirements - delivering a prioritised finding report with remediation recommendations. An internal audit checks compliance against your own SOPs. PHARPRO gap assessments simulate how an external inspector would view your operations, identifying risks your own team may overlook.

PHARPRO data integrity reviews are benchmarked against FDA's 2018 Data Integrity Guidance, MHRA GxP Data Integrity Guidance, WHO Technical Report 1010 Annex 4, and EU GMP Chapter 4 and Annex 11. The review covers ALCOA+ principles, audit trail controls, system access management, and backup and recovery procedures.

PHARPRO supports CAPA development from root cause analysis through to effectiveness check using structured methodologies including Ishikawa analysis and the 5-Why technique - producing a corrective action plan, implementation evidence, and verification record formatted to FDA, EU GMP, and ICH Q10 expectations.

An inspection readiness assessment is a structured, independent review of your quality systems, documentation, and operational practices - conducted as if by an FDA, EU GMP, or WHO inspector. PHARPRO evaluates SOP coverage, batch record quality, deviation and CAPA management, training records, data integrity controls, and laboratory practices, then delivers a prioritised report with remediation guidance before the real inspection takes place.

A focused QA gap assessment typically takes 2–3 weeks from kick-off to final report delivery. Scope, site size, and number of product types affect duration. PHARPRO provides a clear timeline in the project proposal. Urgent pre-inspection assessments can be mobilised faster - contact us to discuss your timeline.

ALCOA+ is the data integrity framework used by FDA, MHRA, EU GMP, and WHO to define the attributes all GxP data must possess. ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate. The '+' adds Complete, Consistent, Enduring, and Available. PHARPRO data integrity audits assess your systems and processes against every ALCOA+ attribute.

An external QA consultant adds independent perspective that internal teams cannot provide. Regulators expect companies to identify and close gaps proactively - an outside reviewer simulates the inspector's viewpoint and surfaces blind spots that familiarity prevents your own team from seeing. PHARPRO works alongside internal QA teams to strengthen existing systems, not replace them.

A deviation is an unplanned departure from an approved procedure or specification - documented, investigated, and risk-assessed. A CAPA (Corrective and Preventive Action) is the structured response: the Corrective Action addresses the immediate problem, and the Preventive Action eliminates the root cause to prevent recurrence. PHARPRO supports the full CAPA lifecycle from root cause analysis through effectiveness check, formatted to FDA, EU GMP, and ICH Q10 expectations.

A PHARPRO pharmaceutical QA gap assessment is priced based on scope - systems reviewed, site size, and applicable regulatory frameworks. A focused gap assessment covering core GMP areas (documentation, CAPA, training, batch records) typically ranges from $3,000–$8,000 USD. Pre-inspection readiness assessments and full-site QA programme reviews are scoped individually. PHARPRO provides a fixed-price proposal with a clear deliverable list - contact us for a free scoping call.

PHARPRO is a specialist pharmaceutical QA consulting firm based in Amman, Jordan, delivering gap assessments, inspection readiness reviews, CAPA support, and SOP development across the MENA region - Jordan, UAE, Saudi Arabia, Egypt, and Kuwait. All engagements are aligned with FDA, EU GMP, WHO, and applicable national authority (JFDA, SFDA, MOH) requirements. Remote delivery is available for all documentation-focused services.

Responding to an FDA 483 or Warning Letter requires a structured CAPA response that addresses root cause - not just the surface finding. PHARPRO supports 483 and Warning Letter responses by conducting independent root cause analysis, drafting CAPA commitments with realistic timelines, reviewing supporting documentation, and formatting the response to meet FDA's expectations for completeness and corrective action specificity. Contact us immediately if you have received a 483.

A WHO prequalification inspection assesses whether a pharmaceutical manufacturing site meets WHO GMP requirements covering quality systems, facilities, equipment, documentation, production, QC, and distribution. Inspectors review SOPs, batch records, validation files, deviation logs, and CAPA systems - and conduct facility walk-throughs. PHARPRO's inspection readiness support includes a mock WHO inspection, gap identification, documentation remediation, and team preparation before the actual inspection visit.

Client Reviews

What our clients say

"PHARPRO supported us with strong technical understanding and practical execution. Their work added real clarity to our validation and compliance activities."

Axantia Group

Pharmaceutical Manufacturer

"Professional, responsive, and perfectly aligned with the demands of our regulated environment. PHARPRO delivered without ambiguity."

Dar Al Dawa

Pharmaceutical Manufacturer

"PHARPRO helped us approach validation and quality in a more structured, inspection-focused way. Their risk-based methodology was exactly right."

Al Hayat Pharmaceuticals

Pharmaceutical Manufacturer

Related Insights